# The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation

Study · id `cardio:ct-nct02982434` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02982434](<https://clinicaltrials.gov/study/NCT02982434>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02982434

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

## Technical summary

Registry record NCT02982434. Randomized; double masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT02982434, source copy `cardio:ctgov-nct02982434-2016-12-05`, retrieved 2026-10-26)
- Start date: 2016-09 (registry gives no type) (ClinicalTrials.gov record NCT02982434, source copy `cardio:ctgov-nct02982434-2016-12-05`, retrieved 2026-10-26)
- Primary completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02982434, source copy `cardio:ctgov-nct02982434-2016-12-05`, retrieved 2026-10-26)
- Completion: 2018-02 (anticipated) (ClinicalTrials.gov record NCT02982434, source copy `cardio:ctgov-nct02982434-2016-12-05`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT02982434, source copy `cardio:ctgov-nct02982434-2016-12-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02982434-2016-12-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
- Condition: Atrial Fibrillation
- Condition: Ischemic Heart Disease
- Intervention (Drug): Pharmaceutical composition containing botulinum toxin
- Intervention (Drug): 0.9% normal saline
- Intervention (Procedure): Coronary artery bypass grafting
- Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Meshalkin Research Institute of Pathology of Circulation (`cardio:org-meshalkin-research-institute-of-pathology-of-circulation`)

## Provenance

Content hash: cc10a7b0223f577c5fc2ebb394f4fefcbe7e64a7833422abbfea59f7a364fa83
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
